Paper Details

  1. Home
  2. Paper Details

Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.

Author: ChenXuanrong, ChenYawei, GongUe, JiangAili, LiGuilai, NiuYuanjie, ShangZhiqun, SunGuijiang, WeiFang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

The main treatment for prostate cancer that has spread is hormone therapy. However, most patients eventually develop resistance. Studies have shown that adding chemotherapy to hormone therapy improves survival for people with prostate cancer that is sensitive to hormones. However, many patients develop new cancer despite hormone therapy, highlighting the need for better treatments.
Paper Details　
Original Abstract of the Article :
Patients with metastasis prostate cancer underwent androgen deprivation therapy (ADT) in the considering of the leading role of androgen receptor pathway. However, the resistance occurred within 1 year or more. The combination of cytotoxic chemotherapy and abiraterone for ADT therapy was performed i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fon-2018-0619

データ提供：米国国立医学図書館（NLM）

Androgen Deprivation Therapy with Chemotherapy or Abiraterone for Patients with Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis

Prostate cancer, like a relentless desert wind, can spread and threaten the body's health. This study delves into the complex world of androgen deprivation therapy (ADT), a common treatment for prostate cancer, exploring the effectiveness of combining ADT with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer. The researchers, like seasoned desert explorers, systematically review the available literature to assess the efficacy of these treatment strategies.

Navigating the Desert of Prostate Cancer Treatment

The study found that combining ADT with chemotherapy or abiraterone significantly improves overall survival for patients with metastatic hormone-naive prostate cancer. This suggests that these combinations, like powerful tools in a desert explorer's kit, can effectively combat the spread of prostate cancer and extend patient survival. The study highlights the importance of considering these treatment options early in the disease course, potentially offering a more favorable outcome for patients.

Finding New Paths in the Desert of Prostate Cancer

The study underscores the ongoing search for effective treatments for prostate cancer, particularly for patients with metastatic disease. It highlights the need for continued research to develop new therapies and refine existing treatment strategies, seeking to find a path to greater relief and improved quality of life for those living with this challenging condition. The desert of prostate cancer is vast and unforgiving, but ongoing research offers hope for finding new and effective therapies.

Dr.Camel's Conclusion

This research, like a guide leading us through the treacherous landscape of prostate cancer, highlights the potential benefits of combining ADT with chemotherapy or abiraterone for patients with metastatic disease. The study underscores the importance of early and effective treatment strategies to improve patient outcomes. Navigating the desert of prostate cancer requires a careful approach, combining proven therapies with a commitment to ongoing research and innovation.

Date :
  1. Date Completed 2019-08-02
  2. Date Revised 2019-08-02
Further Info :

Pubmed ID

30741558

DOI: Digital Object Identifier

10.2217/fon-2018-0619

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.